Topics

Janssen Submits sBLA to the FDA for Darzalex Combination Regimen for Treatment of Relapsed/Refractory Multiple Myeloma

16:32 EST 11 Feb 2020 | Speciality Pharma Journal

RARITAN, N.J., Feb. 10, 2020  — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase …

Original Article: Janssen Submits sBLA to the FDA for Darzalex Combination Regimen for Treatment of Relapsed/Refractory Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Janssen Submits sBLA to the FDA for Darzalex Combination Regimen for Treatment of Relapsed/Refractory Multiple Myeloma"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...